Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Psoriasis Association | UNKNOWN |
Not provided
Not provided
Not provided
The METRED-P study will test the feasibility of implementing a Mediterranean style diet and/or time-restricted eating as dietary patterns in individuals with psoriasis. This study will address the following research questions:
Participants will attend an initial clinic visit for a fasting blood sample, psoriasis examination, body composition measurements, and will complete short multiple-choice questionnaires on the severity of their psoriasis. A Research Nutritionist will deliver the diet interventions as diet consultation sessions. These sessions are reoccurring throughout the study as virtual consultation booster sessions, which are supplemented with wellbeing check-in calls. Participants will complete short questionnaires on the severity of their psoriasis and will record their dietary intake for 4 days, before the start of the study, and on week 1, week 6, and week 12 of the study. The allocated diet should be adhered to for 12 weeks until the end of the study, where participants will return and attend a final clinic visit to repeat the measures obtained during the initial clinic visit.
Researchers will compare the feasibility of implementing a Mediterranean style diet and a Mediterranean style diet with time-restricted eating, with a UK diet with time-restricted eating.
The METRED-P study is a 12-week dietary intervention in individuals with mild-moderate psoriasis. Participants will be randomly allocated to one of three groups: a Mediterranean style diet only, a Mediterranean style diet with time-restricted eating or a UK diet with time-restricted eating.
The funding organisation (the Psoriasis Association) will support with recruitment by advertising the study on their website, on their various social media platforms, and in their monthly newsletter. Flyers will be displayed in Participant Identification Centers as well as on campus at King's College London. Social media will be used to promote the study and the study will also be advertised in the biweekly recruitment newsletter that is circulated to the staff and student population at King's College London.
Individuals responding to the study advertisements will be emailed an information sheet to evaluate if the METRED-P study is suitable for them. An eligibility video call will be arranged with the Research Nutritionist, to verify the volunteer meets the inclusion criteria, explain the information sheet and the informed consent process, and address any questions. Eligible respondents will be invited to an online video screening consultation on Microsoft Teams with the Research Nutritionist and Consultant Dermatologist to confirm their eligibility. The eligibility call and screening consultation will not be recorded and will be conducted confidentially, in a private office. Volunteers who meet the inclusion criteria will be invited to attend a screening clinic visit in the Metabolic Research Unit, 4th floor (Corridor A) at King's College London, 150 Stamford Street, SE1 9NH. The volunteer will be asked to complete the consent form and provide a fasted blood sample for a total of 13mL of blood (approximately 3.5 teaspoons) . A brief physical examination will be undertaken inclusive of weight, height, waist and hip circumference, body composition (% body fat) and clinic blood pressure. Participants will enrol in the the METRED-P study according to the inclusion and exclusion criteria and upon completing a 4-day diet diary assessment of habitual nutrient intake.
Eligible participants who passed the screening stages, will complete a hand-written 4-day diet diary and submit it by email to the Research Nutritionist prior to the initial clinic visit. Participants will arrive to the clinic at approximately 08:00AM, after a 12-hour overnight fast. A fasting blood sample will be taken intravenously for a total of 18mL of blood (approximately 4.5 teaspoons). Psoriasis severity will be assessed by the Consultant Dermatologist. Body composition and clinic blood pressure measures will be taken by the Research Nutritionist. Based on the pre-clinic 4-day diet diary, participants will receive personalised dietary guidance on their allocated dietary intervention, which should be adhered to for the duration of the study. On week 4 and week 8 of the study, virtual dietary consultation booster sessions will be arranged with the Research Nutritionist to reinforce the dietary advice and to maximise adherence with the allocated dietary interventions. Participants will also complete short multiple-choice questionnaires on the severity of their psoriasis. Wellbeing check-in calls are scheduled on week 2, week 6 and week 10 with the Research Nutritionist to ensure participant well-being and address any compliance issues. Participants will return for a clinic visit at the end of the study, to repeat the measures obtained at the initial visit and complete an exit questionnaire.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The Mediterranean style diet | Experimental | Participants in the Mediterranean style diet arm (n = 12) will receive dietary advice to follow a Mediterranean style diet by the Research Nutritionist. |
|
| The Mediterranean style diet with time-restricted eating | Experimental | Participants in the Mediterranean style diet with time-restricted eating arm (n = 12) will receive dietary advice to follow a Mediterranean style diet combined with time-restricted eating by the Research Nutritionist. |
|
| The UK diet with time-restricted eating | Active Comparator | Participants in the UK diet with time-restricted eating arm (n = 12) will receive dietary advice to follow a UK diet combined with time-restricted eating by the Research Nutritionist. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Mediterranean style diet | Other | Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week. Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study. |
| Measure | Description | Time Frame |
|---|---|---|
| Average adherence to the diet intervention after 1 week, as assessed by the MEditerranean Diet Adherence Screener (MEDAS). | 0-5 points = low adherence, 6-9 points = moderate adherence and 10-14 points = high adherence. | 1 week |
| Average adherence to the diet intervention after 6 weeks, as assessed by the MEditerranean Diet Adherence Screener (MEDAS). | 0-5 points = low adherence, 6-9 points = moderate adherence and 10-14 points = high adherence. | 6 weeks |
| Average adherence to the diet intervention after 12 weeks, as assessed by the MEditerranean Diet Adherence Screener (MEDAS). | 0-5 points = low adherence, 6-9 points = moderate adherence and 10-14 points = high adherence. | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| The acceptability of the allocated dietary intervention, as assessed by participant records. | Expressed as rates of participant recruitment, attrition, and compliance. | 12 weeks |
| The practicality of delivering the dietary interventions, as assessed with a exit questionnaire. |
| Measure | Description | Time Frame |
|---|---|---|
| Change between baseline and week 12 psoriasis severity, as assessed by the Psoriasis Area Severity Index (PASI). | 0-4 = mild psoriasis, 5-10 = moderate psoriasis, and >10 = severe psoriasis. | 12 weeks |
| Change in baseline self-reported psoriasis severity at 4 weeks, as assessed by the self-assessed Simplified Psoriasis Index (sa-SPI). |
Inclusion Criteria:
Exclusion Criteria:
is taking Cyclosporine or Stelara in the past 3 months
is receiving or has received photo (light) therapies for psoriasis in the past 3 months
is a shift worker or is involved in shift work
is planning on international travel during the study period
is not weight stable or has attempted to lose weight during the past 6 months
diagnosis of a gluten, nut, peanut, fish, or shellfish allergy
diagnosis of a gluten or dairy intolerance
is following a restrictive diet/restricting food groups i.e vegan, vegetarian, gluten-free , or a Mediterranean style diet
is following any intermittent fasting regimes inclusive of 5:2, alternate day fasting or modified alternate day fasting, time-restricted eating over the past 6 months
reports a habitual eating window < 12 h per day
reports a baseline healthy diet (e.g. > 5 servings of fruits and vegetables per day, 1 serving of nuts per day , 2 servings of whole grains per day, 2 servings of fish per week, > 1 servings of nuts per day and rarely eats sweet snacks, cakes, fried foods and red meat).
taking fish oil or other dietary supplements (except daily multivitamins providing no more than 200% of UK dietary recommended values)
currently pregnant, currently breastfeeding or planning to become pregnant in the next 4 months
is or has been diagnosed in the past with any of the following:
history of bariatric surgery
history of substance abuse or alcoholism (past history of alcohol intake >60 units/men or 50 units/women), within the last 12 months
taking medication likely to interfere with study outcomes e.g. steroids (except occasional use of inhalers), anti-inflammatories or immune-suppressive drugs
taking blood pressure medication, but has not been on a stable dosage during the last 3 months
not on a stable topical treatment regimen for psoriasis (if prescribed)
currently participating in a pharmaceutical study for psoriasis treatments (topical, light, tablet, or injection therapies) or has participated in a pharmaceutical study < 3 months ago
currently participating in another diet intervention study or has participated in a diet intervention study < 3 months ago
unwilling to record dietary intakes using handwritten diet diaries
not fluent in the English language
reports to have fainted in the past during an intravenous blood test
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wendy L Hall, PhD | Reader in Nutritional Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Metabolic Research Unit, Franklin-Wilkins Building, King's College London. 150 Stamford Street, Waterloo, London. | London | Westminser | SE1 9NH | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10468786 | Background | Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999 Aug;141(2):185-91. doi: 10.1046/j.1365-2133.1999.02963.x. | |
| 25549367 | Background | Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, Donahue KR, Kimball AB. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015 Apr;151(4):375-81. doi: 10.1001/jamadermatol.2014.3513. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D000093763 | Intermittent Fasting |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005215 | Fasting |
| D005247 | Feeding Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Given the nature of dietary interventions, blinding will not always be possible, and this study will be conducted in an unblinded manner. Only the Consultant Dermatologist (Outcome Assessor) undertaking the psoriasis severity examinations will be blinded to the allocated diet interventions of the participants. All statistical data analysis will be carried out blinded using data codes to ensure that the intervention allocation is concealed from the researcher carrying out the statistical analysis.
|
| The UK diet | Other | Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week. Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study. |
|
| Time-restricted eating | Other | Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees |
|
Expressed as the percentages of participant responses. |
| 12 weeks |
0-9 = mild psoriasis, 10-19 = moderate psoriasis and >20 = severe psoriasis. |
| 4 weeks |
| Change in baseline self-reported psoriasis severity at 8 weeks, as assessed by the self-assessed Simplified Psoriasis Index (sa-SPI). | 0-9 = mild psoriasis, 10-19 = moderate psoriasis and >20 = severe psoriasis. | 8 weeks |
| Change in baseline self-reported psoriasis severity at 12 weeks, as assessed by the self-assessed Simplified Psoriasis Index (sa-SPI). | 0-9 = mild psoriasis, 10-19 = moderate psoriasis and >20 = severe psoriasis. | 12 weeks |
| Change between baseline and week 12 psoriasis severity, as assessed by the Physician's Global Assessment (PGA). | 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. | 12 weeks |
| Change in baseline self-reported psoriasis severity at 4 weeks, as assessed by the Dermatology Life Quality Index (DLQI). | 0-1 points = no effect at all , 2-5 points = small effect , 6-10 points = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on the participant's life. | 4 weeks |
| Change in baseline self-reported psoriasis severity at 8 weeks, as assessed by the Dermatology Life Quality Index (DLQI). | 0-1 points = no effect at all , 2-5 points = small effect , 6-10 points = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on the participant's life. | 8 weeks |
| Change in baseline self-reported psoriasis severity at 12 weeks, as assessed by the Dermatology Life Quality Index (DLQI). | 0-1 points = no effect at all , 2-5 points = small effect , 6-10 points = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on the participant's life. | 12 weeks |
| Change in baseline well-being at 4 weeks, as assessed by the World Health Organisation-5 (WHO-5). | 0 represents the worst possible, and 25 representing best possible quality of life. | 4 weeks |
| Change in baseline well-being at 8 weeks, as assessed by the World Health Organisation-5 (WHO-5). | 0 represents the worst possible, and 25 representing best possible quality of life. | 8 weeks |
| Change in baseline well-being at 12 weeks, as assessed by the World Health Organisation-5 (WHO-5). | 0 represents the worst possible, and 25 representing best possible quality of life. | 12 weeks |
| Change in baseline body weight, at 4 weeks, as assessed by self-measurement. | Calculated as the change between baseline body weight and body weight at week 4. | 4 weeks |
| Change in baseline body weight at 8 weeks, as assessed by self-measurement. | Calculated as the change between baseline body weight and body weight at week 8. | 8 weeks |
| Change in baseline body weight at 12 weeks, as assessed in clinic. | Calculated as the change between baseline body weight and body weight at 12 weeks. | 12 weeks |
| Change in baseline Body Mass Index (BMI), as assessed by self-measurement. | Calculated as the change between baseline BMI and BMI at 4 weeks. | 4 weeks |
| Change in baseline Body Mass Index (BMI), as assessed by self-measurement. | Calculated as the change between baseline BMI and BMI at 8 weeks. | 8 weeks |
| Change in baseline Body Mass Index (BMI), as assessed in clinic. | Calculated as the change between baseline BMI and BMI at 12 weeks. | 12 weeks |
| Change in waist-to-hip ratio. | Change between baseline and week 12 waist-to-hip ratio. | 12 weeks |
| Change % body fat, as assessed by bioelectrical impedance analysis. | Change between baseline and week 12 body fat (%). | 12 weeks |
| Change in % lean body mass, as assessed by bioelectrical impedance analysis. | Change between baseline and week lean body mass (%). | 12 weeks |
| Change in clinic blood pressure. | Change between baseline and week 12 clinic blood pressure. | 12 weeks |
| Change in fasting plasma glucose. | Change between baseline and week 12 fasting plasma glucose. | 12 weeks |
| Change in fasting serum insulin. | Change between baseline and week 12 fasting serum insulin. | 12 weeks |
| Change in fasting serum total cholesterol. | Change between baseline and week 12 fasting serum total cholesterol. | 12 weeks |
| Change in fasting serum low density lipoprotein (LDL) cholesterol. | Change between baseline and week 12 fasting serum low density lipoprotein (LDL) cholesterol. | 12 weeks |
| Change in fasting serum high density lipoprotein (HDL) cholesterol. | Change between baseline and week 12 fasting serum high density lipoprotein (HDL) cholesterol. | 12 weeks |
| Change in fasting serum triglycerides. | Change between baseline and week 12 fasting serum triglycerides. | 12 weeks |
| Change in fasting serum high-sensitivity C-Reactive Protein. | Change between baseline and week 12 fasting serum high-sensitivity C-reactive protein. | 12 weeks |
| Change in fasting serum Tumour Necrosis Factor - alpha (TNF - α). | Change between baseline and week 12 fasting serum TNF - α. | 12 weeks |
| Change in fasting serum Interferon - gamma (IFN - γ). | Change between baseline and week 12 fasting serum IFN - γ. | 12 weeks |
| Change in fasting serum Interleukin - 6 (IL-6). | Change between baseline and week 12 fasting serum IL-6. | 12 weeks |
| Change in fasting serum Interleukin - 12 (IL-12). | Change between baseline and week 12 fasting serum IL-12. | 12 weeks |
| Change in fasting serum Interleukin - 17 (IL-17). | Change between baseline and week 12 fasting serum IL-17. | 12 weeks |
| Change in fasting serum Interleukin - 17 (IL-23). | Change between baseline and week 12 fasting serum IL-23. | 12 weeks |
| 8033378 | Background | Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6. doi: 10.1111/j.1365-2230.1994.tb01167.x. |
| 25831962 | Background | Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585. Epub 2015 Mar 28. |
| 23807685 | Background | Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol. 2013 Aug;133(8):1956-62. doi: 10.1038/jid.2013.138. Epub 2013 Mar 20. |
| D001519 | Behavior |